COMPANY

Antigenix Therapeutics

Keywords: antibody oncology cancer antibody-drug conjugate ADC monoclonal antibody

Location: Princeton, NJ · source · Oct 24, 2025

Profile checked Oct 10, 2026

Funding and NIH signals

SEC Form D raise Raised $3.36M (Form D filed Oct 24, 2025). SEC Form D 0002073993-25-000001 (Oct 24, 2025)
Evidence (1 event)
- Oct 24, 2025 · SEC Form D 0002073993-25-000001
  Name of Issuer: Antigenix Therapeutics, Inc.; CIK: 2073993; Address: Princeton, NJ; Submission type: D; Filing date: 2025-10-24; Industry Group: Other Health Care; Date of First Sale: 2025-10-22; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 8363695; Total Amount Sold: 3363695; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Dec 17, 2025 Raise Private equity round — Seed: $7M (total, as published), announced Dec 17, 2025. Source: company's own press page. source ↗

Raised: $7.0M. Last 2 years.

Dec 17, 2025 Private equity round — Seed: $7M (total, as published), announced Dec 17, 2025. Source: company's own press page. source ↗